G1 Therapeutics, Inc. GTHX
Sep 17, 2024, 3:56 PM EDT
52-week range unavailable
- Market cap
- 377.75M
- Revenue (ttm)
- 58.20M
- Profit margin
- -76.93%
- Shares out
- 52.76M
- Volume
- 1.10M
- Open
- 7.15
- Previous close
- 7.16
- Day's range
- 7.14 – 7.16
- Beta
- 1.68
- Analysts
- Hold
- Price target
- 7.15 (-0.1%)
- Earnings date
- Nov 6, 2024
YTD +4.04 (+129.90%)
Key statistics
- Enterprise value
- 364.46M
- PEG ratio
- 0.00
- Price / sales
- 6.48
- Price / book
- 15.31
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -61.00%
- Free cash flow
- -19.83M
- Total cash
- 60.73M
- Total debt
- 47.96M
- Return on equity
- -109.01%
- Short % of float
- 6.52%
- 50-day average
- 5.84
- 200-day average
- 4.10
Analyst view
Consensus: hold
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 6, 2024
Expected Nov 6, 2024. Consensus EPS estimate -0.09.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.12 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.17 | — | — | — |
| May 1, 2024 | Mar 1, 2024 | -0.19 | — | — | — |
| Feb 28, 2024 | Dec 1, 2023 | -0.27 | — | — | — |
| Nov 1, 2023 | Sep 1, 2023 | -0.31 | — | — | — |
| Aug 2, 2023 | Jun 1, 2023 | -0.17 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2023 | JP Morgan | down | Neutral | Underweight |
| Aug 2, 2023 | Wedbush | reit | Outperform | Outperform |
| Aug 2, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 1, 2023 | EF Hutton | reit | — | Buy |
| Aug 1, 2023 | Needham | main | Buy | Buy |
| Jun 25, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About G1 Therapeutics, Inc.
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- g1therapeutics.com
News
Earnings Scheduled For February 28, 2024 
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
Why ZoomInfo Technologies Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Monday's Intraday Session 
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Earnings Scheduled For November 1, 2023
- Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Thursday
Your note
Sign in to keep a note on GTHX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AVAGLIANO MARK | Officer | Stock Award(Grant) | Sep 17, 2024 | 0 |
| BAILEY JOHN E JR | Chief Executive Officer | Stock Award(Grant) | Sep 17, 2024 | 0 |
| MALIK RAJESH K. | Officer | Stock Award(Grant) | Sep 17, 2024 | 0 |
| MUIR GLENN P | Director | Stock Award(Grant) | Jun 12, 2024 | 205,358 |
| MURDOCK TERRY L. | Chief Operating Officer | Stock Award(Grant) | Sep 17, 2024 | 0 |
| NICHOLSON GARRY A | Director | Stock Award(Grant) | Jun 12, 2024 | 34,389 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fisher Asset Management, LLC | 4.91% | 2,543,006 | 6.33M | Jun 29, 2023 |
| JP Morgan Chase & Company | 4.09% | 2,115,873 | 5.27M | Jun 29, 2023 |
| Vanguard Group Inc | 3.77% | 1,950,068 | 4.86M | Jun 29, 2023 |
| Blackrock Inc. | 2.29% | 1,185,645 | 2.95M | Jun 29, 2023 |
| Raymond James & Associates, Inc. | 1.53% | 792,114 | 1.97M | Jun 29, 2023 |
| Shaw D.E. & Co., Inc. | 1.19% | 616,503 | 1.54M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.50% | 1,295,502 | 3.23M | Jun 29, 2023 |
| JP Morgan Small Cap Growth Fund | 2.38% | 1,233,467 | 3.07M | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 1.13% | 583,255 | 1.45M | Jun 29, 2023 |
| iShares NASDAQ Biotechnology ETF | 0.58% | 302,415 | 505.03K | Aug 30, 2023 |
| Fidelity Extended Market Index Fund | 0.47% | 242,045 | 614.79K | May 30, 2023 |
| Tekla Life Sciences Investors | 0.43% | 223,377 | 556.21K | Jun 29, 2023 |